Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 600

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 600
---
 any residual obligations under the Business Combination Agreement. On August 8, 2024, OmnigenicsAI Corp, Heritas Ltd., and MultiplAI Health Ltd. signed a binding term sheet outlining the terms and conditions for a Reseller License Agreement to settle MultiplAI Ltd.’s outstanding debt to Heritas Ltd,, amounting to US$395,260, due by February 2025. As part of the agreement, MultiplAI Ltd. will grant OmnigenicsAI Corp, exclusive rights to commercialize its proprietary blood -basedscreening tests in Latin America, along with providing 600 pre -paidtests for business development purposes. These exclusive rights are granted for a period of five years, commencing on January 1, 2025. Shared-based incentives In October 2024, Heritas Ltd., at the sole discretion of the shareholders of Heritas Ltd., entered into Deferred Share Right Agreements (“DSRs”) with three key employees of Heritas Argentina (referred to as the “Key Employee”, on an individual basis). These agreements were structured to incentivize and retain critical talent identified as essential for the Group’s success following the Closing. F-102 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 22.Events after the reporting period (cont.) Under the terms of these DSRs, (i) each employee will receive a deferred share grant of 30,000shares of Heritas Ltd. (the “Shares”), for a total of 90,000shares to be granted; (ii) the Shares will vest and be transferred one year after the Closing (the “Vesting Date”), provided the Key Employee remains employed with Heritas Ltd., or its affiliates, including the Group; and in the event of resignation or termination for cause before the Vesting Date, the Shares will be forfeited. Conversely, in the case of termination without cause, the rights will vest immediately. These share -basedagreement have a service inception date after year ended June30, 2024. As of the date of issuance of these combined financial statements, no additional share -basedincentives have been provided. F-103 OmnigenicsAI Corp 6,332,556 Ordinary Shares
17,574,991 Warrants to Purchase Ordinary Shares
17,574,991 Ordinary Shares Underlying Warrants of OmnigenicsAI Corp ________________________________________________ PROSPECTUS ________________________________________________ , 2025 Annex A EXECUTION VERSION BUSINESS COMBINATION AGREEMENT by